BioTech

Sun Pharma Launches Osmotic Delivery Formulation Of Methylphenidate In Canada

September 24, 2026 — 09:25 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Sun Pharmaceutical Industries (SUNPHARMA.NS) announced the commercial availability of Taro-Methylphenidate ER for Canadian patients in Ontario and Quebec. Taro-Methylphenidate ER is the only bioequivalent to Concerta with an osmotic delivery system indicated for the treatment of Attention Deficit Hyperactivity Disorder in patients six years of age and older. Taro-Methylphenidate ER is currently reimbursed by Régie de l'assurance maladie du Québec in Quebec and the Ontario Public Drug Program.

"We continue to work with public and private formularies to support patient access in every province across the country" said Barb Pimentel, General Manager Generics and Consumer Healthcare, Sun Pharma.

Sun Pharma shares closed trading at INR 1,851.00 on NSE, down 0.75%.

For More Such Health News, visit rttnews.com.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

BioTech

Latest Articles
Data is currently not available